Cerebral vasospasm after aneurysmal subarachnoid hemorrhage: An overview of pharmacologic management

Pharmacotherapy

Volumn 26, Issue 2, 2006, Pages 182-203

  Liu DeRyke, Xi ^a   Rhoney, Denise H ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Calcium channel blockers; Cerebral vasospasm; Intraarterial vasodilating agents; Subarachnoid hemorrhage; Triple H therapy

Indexed keywords

ALTEPLASE; AMRINONE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; GLUCOSE; HYPERTENSIVE AGENT; MAGNESIUM; MILRINONE; NICARDIPINE; NIMODIPINE; NITROPRUSSIDE SODIUM; NORADRENALIN; PAPAVERINE; PHENYLEPHRINE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RINGER LACTATE SOLUTION; STEROID; TIRIZALAD; UNCLASSIFIED DRUG; VASODILATOR AGENT; VERAPAMIL;

APHASIA; BILIARY TRACT DISEASE; BLEEDING; BLINDNESS; BLOOD PRESSURE; BLOOD VOLUME; BRAIN ANGIOGRAPHY; BRAIN ARTERY ANEURYSM; BRAIN BLOOD FLOW; BRAIN EDEMA; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN VASOSPASM; CATHETER INFECTION; CENTRAL VENOUS PRESSURE; CEREBELLUM HEMORRHAGE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DISSECTING ANEURYSM; DOPPLER ECHOGRAPHY; DRUG INDUCED HEADACHE; DRUG MECHANISM; EPIDURAL HEMATOMA; FIBRINOLYTIC THERAPY; FLUID THERAPY; GASTROINTESTINAL DISEASE; HEART MUSCLE ISCHEMIA; HEMIPARESIS; HEMODILUTION; HUMAN; HYPERTENSION; HYPERVOLEMIA; HYPOTENSION; INDUCED HYPERTENSION; INTRACRANIAL HYPERTENSION; LIVER DYSFUNCTION; LUNG CAPILLARY PRESSURE; META ANALYSIS; MYDRIASIS; NEUROIMAGING; NEUROLOGICAL COMPLICATION; NONHUMAN; PATHOGENESIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PLASMA VOLUME; PROPHYLAXIS; PSYCHOMOTOR DISORDER; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY ARREST; REVIEW; RISK FACTOR; SEIZURE; SUBARACHNOID HEMORRHAGE; SUBGALEA FLUID ACCUMULATION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOSIS;

HUMANS; SUBARACHNOID HEMORRHAGE; VASOSPASM, INTRACRANIAL;

EID: 32044458425     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.2.182     Document Type: Review

References (116)

1. Zweifler RM. Management of acute stroke. South Med J 2003;96:380-5.
2. MacDonald RL. Cerebral vasospasm. In: Welch KMA, Reis DJ, Siesjo BK, et al, eds. Primer on cerebrovascular diseases. San Diego: Academic Press, 1997:490-502.
3. van Gijn J, Rinkel GJ. Subarachnoid haemorrhage: diagnosis, causes and management. Brain 2001;124:249-78.
4. Linn FH, Rinkel GJ, Algra A, et al. Incidence of subarachnoid hemorrhage: role of region, year, and rate of computed tomography-a meta-analysis. Stroke 1996;27:625-9.
5. Mayberg MR, Batjer HH, Dacey R, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1994;25:2315-28.
6. Rinkel GJ. Intracranial aneurysm screening: indications and advice for practice. Lancet Neurol 2005;4:122-8.
7. Weir B. Subarachnoid hemorrhage: causes and cures. New York: Oxford University Press, Inc., 1998.
8. Kassell NF, Torner JC, Haley EC Jr, et al. The international cooperative study on the timing of aneurysm surgery. 1. Overall management results. J Neurosurg 1990;73:18-36.
9. Solenski NJ, Haley EC Jr, Kassell NF, et al. Medical complications of aneurysmal subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Participants of the multicenter cooperative aneurysm study. Crit Care Med 1995;23:1007-17.
10. Adams HP Jr, Love BB. Medical management of aneurysmal subarachnoid hemorrhage. In: Barnett HJM, Mohr JP, Stein BM, et al, eds. Stroke: pathophysiology, diagnosis, and managment. Philadelphia: Churchill Livingstone, 1998:1243-62.
11. Adams HP Jr, Kassell NF, Torner JC, et al. Predicting cerebral ischemia after aneurysmal subarachnoid hemorrhage: influences of clinical condition, CT results, and antifibrinolytic therapy: a report of the cooperative aneurysm study. Neurology 1987;37:1586-91.
12. Mohr JP, Kistler JP. Intracranial aneurysms. In: Barnett HJM, MohrJP, Stein BM, et al, eds. Stroke: pathophysiology, diagnosis, and managment. Philadelphia: Churchill Livingstone, 1998;701-23.
13. Treggiari-Venzi MM, Suter PM, Romand JA. Review of medical prevention of vasospasm after aneurysmal subarachnoid hemorrhage: a problem of neurointensive care. Neurosurgery 2001;48:249-62.
14. Al-Yamany M, Wallace MC. Management of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. Intensive Care Med 1999;25:1463-6.
15. Grasso G. An overview of new pharmacological treatments for cerebrovascular dysfunction after experimental subarachnoid hemorrhage. Brain Res Brain Res Rev 2004;44:49-63.
16. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980;6:1-9.
17. Janjua N, Mayer SA. Cerebral vasospasm after subarachnoid hemorrhage. Curr Opin Crit Care 2003;9:113-19.
18. Dorsch NW. Therapeutic approaches to vasospasm in subarachnoid hemorrhage. Curr Opin Crit Care 2002;8:128-33.
19. Taneda M. Effect of early operation for ruptured aneurysms on prevention of delayed ischemic symptoms. J Neurosurg 1982;57:622-8.
20. Dumont AS, Dumont RJ, Chow MM, et al. Cerebral vasospasm after subarachnoid hemorrhage: putative role of inflammation. Neurosurgery 2003;53:123-35.
21. Mayberg MR. Cerebral vasospasm. Neurosurg Clin N Am 1998;9:615-27.
22. Fassbender K, Hodapp B, Rossol S, et al. Endothelin-1 in subarachnoid hemorrhage: an acute-phase reactant produced by cerebrospinal fluid leukocytes. Stroke 2000;31:2971-5.
23. Le Roux PD, Elliott JP, Eskridge JM, et al. Risks and benefits of diagnostic angiography after aneurysm surgery: a retrospective analysis of 597 studies. Neurosurgery 1998;42:1248-55.
24. Peerdeman SM, van Tulder MW, Vandertop WP. Cerebral microdialysis as a monitoring method in subarachnoid hemorrhage patients, and correlation with clinical events: a systematic review. J Neurol 2003;250:797-805.
25. Meyer FB. Calcium antagonists and vasospasm. Neurosurg Clin N Am 1990;1:367-76.
26. Zornow MH, Prough DS. Neuroprotective properties of calcium-channel blockers. New Horiz 1996;4:107-14.
27. Feigin VL, Rinkel GJ, Algra A, et al. Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage: a systematic review. Neurology 1998;50:876-83.
28. Juvela S, Kaste M, Hillbom M. Effect of nimodipine on platelet function in patients with subarachnoid hemorrhage. Stroke 1990;21:1283-8.
29. Allen GS, Ahn HS, Preziosi TJ, et al. Cerebral arterial spasm: a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 1983;308:619-24.
30. Philippon J, Grob R, Dagreou F, et al. Prevention of vasospasm in subarachnoid haemorrhage: a controlled study with nimodipine. Acta Neurochir (Wien) 1986;82:110-14.
31. Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poor-grade aneurysm patients: results of a multicenter double-blind placebo-controlled trial. J Neurosurg 1988;68:505-17.
32. Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 1989;298:636-42.
33. Porchet F, Chiolero R, de Tribolet N. Hypolensive effect of nimodipine during treatment for aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien) 1995;137:62-9.
34. Rinkel GJ, Feigin VL, Algra A, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2005;issue 1:CD000277.
35. Messeter K, Brandt L, Ljunggren B, et al. Prediction and prevention of delayed ischemic dysfunction after aneurysmal subarachnoid hemorrhage and early operation. Neurosurgery 1987;20:548-53.
36. Mee E, Dorrance D, Lowe D, et al. Controlled study of nimodipine in aneurysm patients treated early after subarachnoid hemorrhage. Neurosurgery 1988;22:484-91.
37. Ohman J, Heiskanen O. Effect of nimodipine on the outcome of patients after aneurysmal subarachnoid hemorrhage and surgery. J Neurosurg 1988;69:683-6.
38. Dorsch NW, Compton JS. Treatment of symptomatic vasospasm with nimodipine. Ann Acad Med Singapore 1993;22:407-9.
39. Mercier P, Alhayek G, Rizk T, et al. Are the calcium antagonists really useful in cerebral aneurysmal surgery? A retrospective study. Neurosurgery 1994;34:30-7.
40. Haley EC Jr, Kassell NF, Torner JC. A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage: a report of the cooperative aneurysm study. J Neurosurg 1993;78:537-47.
41. Barker FG II, Ogilvy CS. Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a metaanalysis. J Neurosurg 1996;84:405-14.
42. Lewis PJ, Weir BK, Nosko MG, et al. Intrathccal nimodipine therapy in a primate model of chronic cerebral vasospasm. Neurosurgery 1988;22:492-500.
43. Haley EC Jr, Kassell NF, Torner JC. A randomized trial of nicardipine in subarachnoid hemorrhage: angiographic and transcranial Doppler ultrasound results-a report of the cooperative aneurysm study. J Neurosurg 1993;78:548-53.
44. Handa Y, Weir BK, Nosko M, et al. The effect of timing of clot removal on chronic vasospasm in a primate model. J Neurosurg 1987;67:558-64.
45. Findlay JM, Weir BK, Gordon P, et al. Safety and efficacy of intrathecal thrombolytic therapy in a primate model of cerebral vasospasm. Neurosurgery 1989;24:491-8.
46. Findlay JM, Weir BK, Kanamaru K, et al. The effect of timing of intrathecal fibrinolytic therapy on cerebral vasospasm in a primate model of subarachnoid hemorrhage. Neurosurgery 1990;26:201-6.
47. Mizoi K, Yoshimoto T, Takahashi A, et al. Prospective study on the prevention of cerebral vasospasm by intrathecal fibrinolytic therapy with tissue-type plasminogen activator. J Neurosurg 1993;78:430-7.
48. Sasaki T, Ohta T, Kikuchi H, et al. A phase II clinical trial of recombinant human tissue-type plasminogen activator against cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 1994;35:597-605.
49. Steinberg GK, Vanefsky MA, Marks MP, et al. Failure of intracisternal tissue plasminogen activator to prevent vasospasm in certain patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 1994;34:809-14.
50. Usui M, Saito N, Hoya K, et al. Vasospasm prevention with postoperative intrathecal thrombolytic therapy: a retrospective comparison of urokinase, tissue plasminogen activator, and cisternal drainage alone. Neurosurgery 1994;34:235-45.
51. Findlay JM, Kassell NF, Weir BK, et al. A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Neurosurgery 1995;37:168-78.
52. Mizoi K, Yoshimoto T, Fujiwara S, et al. Prevention of vasospasm by clot removal and intrathecal bolus injection of tissue-type plasminogen activator: preliminary report. Neurosurgery 1991;28:807-13.
53. Bell TE, Kongable GL. Innovations in aneurysmal subarachnoid hemorrhage: intracisternal t-PA for the prevention of vasospasm. J Neurosci Nurs 1996;28:107-13.
54. Amin-Hanjani S, Ogilvy CS, Barker FG II. Does intracisternal thrombolysis prevent vasospasm after aneurysmal subarachnoid hemorrhage? A meta-analysis. Neurosurgery 2004;54:326-35.
55. Sen J, Belli A, Albon H, et al. Triple-H therapy in the management of aneurysmal subarachnoid haemorrhage. Lancet Neurol 2003;2:614-21.
56. Tommasino C, Picozzi P. Physiopathological criteria of vasospasm treatment. J Neurosurg Sci 1998;42:23-6.
57. Romner B, Reinstrup P. Triple H therapy after aneurysmal subarachnoid hemorrhage: a review. Acta Neurochir Suppl 2001;77:237-41.
58. Levy ML, Giannotta SL. Cardiac performance indices during hypervolemic therapy for cerebral vasospasm. J Neurosurg 1991;75:27-31.
59. Kassell NF, Peerless SJ, Durward OJ, et al. Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. Neurosurgery 1982;11:337-43.
60. Muizelaar JP, Becker DP. Induced hypertension for the treatment of cerebral ischemia after subarachnoid hemorrhage: direct effect on cerebral blood flow. Surg Neurol 1986;25:317-25.
61. Awad IA, Carter LP, Spetzler RF, et al. Clinical vasospasm after subarachnoid hemorrhage: response to hypervolemic hcmodilution and arterial hypertension. Stroke 1987;18:365-72.
62. Yamakami I, Isobe K, Yamaura A. Effects of intravascular volume expansion on cerebral blood flow in patients with ruptured cerebral ancurysms. Neurosurgery 1987;21:303-9.
63. Solomon RA, Fink ME, Lennihan L. Early aneurysm surgery and prophylactic hypervolemic hypertensive therapy for the treatment of aneurysmal subarachnoid hemorrhage. Neurosurgery 1988;23:699-704.
64. Origitano TC, Wascher TM, Reichman OH, et al. Sustained increased cerebral blood flow with prophylactic hypertensive hypervolemic hemodilution ("triple-H" therapy) after subarachnoid hemorrhage. Neurosurgery 1990;27:729-40.
65. Medlock MD, Dulebohn SC, Elwood PW. Prophylactic hypervolemia without calcium channel blockers in early aneurysm surgery. Neurosurgery 1992;30:12-16.
66. Mori K, Arai H, Nakajima K, et al. Heinorheological and hemodynamic analysis of hypervolemic hemodilution therapy for cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke 1995;26:1620-6.
67. Rosenwasser RH, Delgado TE, Buchhek WA, et al. Control of hypertension and prophylaxis against vasospasm in cases of subarachnoid hemorrhage: a preliminary report. Neurosurgery 1983;12:658-61.
68. Mayer SA, Solomon RA, Fink ME, et al. Effect of 5% albumin solution on sodium balance and blood volume after subarachnoid hemorrhage. Neurosurgery 1998;42:759-68.
69. Lennihan L, Mayer SA, Fink ME, et al. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. Stroke 2000;31:383-91.
70. Egge A, Waterloo K, Sjoholm H, et al. Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical, prospective, randomized, controlled study. Neurosurgery 2001;49:593-606.
71. Treggiari MM, Walder B, Suter PM, et al. Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. J Neurosurg 2003;98:978-84.
72. Newell DW, Elliott JP, Eskridge JM, et al. Endovascular therapy for aneurysmal vasospasm. Crit Care Clin 1999;15:685-99.
73. Smith TP, Enterline DS. Endovascular treatment of cerebral vasospasm. J Vasc Interv Radiol 2000;11:547-59.
74. Yamamoto Y, Smith RR, Bernanke DH. Mechanism of action of balloon angioplasty in cerebral vasospasm. Neurosurgery 1992;30:1-6.
75. Mathis JM, Jensen ME, Dion JE. Technical considerations on intra-arterial papaverine hydrochloride for cerebral vasospasm. Neuroradiology 1997;39:90-8.
76. McAuliffe W, Townsend M, Eskridge JM, et al. Intracranial pressure changes induced during papaverine infusion for treatment of vasospasm. J Neurosurg 1995;83:430-4.
77. Carhuapoma JR, Qureshi AI, Tamargo RJ, et al. Intra-arterial papavecrine-induced seizures: case report and review of the literature. Surg Neurol 2001;56:159-63.
78. Miller JA, Cross DT, Moran CJ, et al. Severe thrombocytopenia following intraarterial papaverine administration for treatment of vasospasm. J Neurosurg 1995;83:435-7.
79. Tsukahara T, Yoshimura S, Kazekawa K, et al. Intra-arterial papaverine for the treatment of cerebral vasospasm after subarachnoid hemorrhage. J Auton Nerv Syst 1994;49(suppl):S163-6.
80. Clouston JE, Numaguchi Y, Zoarski GH, et al. Intraarterial papaverine infusion for cerebral vasospasm after subarachnoid hemorrhage. Am J Neuroradiol 1995;16:27-38.
81. Milburn JM, Moran CJ, Cross DT III, et al. Increase in diameters of vasospastic intracranial arteries by intraarterial papaverine administration. J Neurosurg 1998;88:38-42.
82. Elliott JP, Newell DW, Lam DJ, et al. Comparison of balloon angioplasty and papaverine infusion for the treatment of vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg 1998;88:277-84.
83. Numaguchi Y, Zoarski GH. Intra-arterial papaverine treatment for cerebral vasospasm: our experience and review of the literature. Neurol Med Chir (Tokyo) 1998;38:189-95.
84. Fandino J, Kaku Y, Schuknecht B, et al. Improvement of cerebral oxygenation patterns and metabolic validation of superselective intraarterial infusion of papaverine for the treatment of cerebral vasospasm. J Neurosurg 1998;89:93-100.
85. Polin RS, Hansen CA, German P, et al. Intra-arterially administered papaverine for the treatment of symptomatic cerebral vasospasm. Neurosurgery 1998;42:1256-67.
86. Liu JK, Tenner MS, Gottfried ON, et al. Efficacy of multiple intraarterial papaverine infusions for improvement in cerebral circulation time in patients with recurrent cerebral vasospasm. J Neurosurg 2004;100:414-21.
87. Khajavi K, Ayzman I, Shearer D, et al. Prevention of chronic cerebral vasospasm in dogs with milrinone. Neurosurgery 1997;40:354-63.
88. Arakawa Y, Kikuta K, Hojo M, et al. Milrinone for the treatment of cerebral vasospasm alter subarachnoid hemorrhage: report of seven cases. Neurosurgery 2001;48:723-30.
89. Yoshida K, Watanabe H, Nakamura S. Intraarterial injection of amrinone for vasospasm induced by subarachnoid hemorrhage. Am J Neuroradiol 1997;18:492-6.
90. Feng L, Fitzsimmons BF, Young WL, et al. Intraarterially administered verapamil as adjunct therapy for cerebral vasospasm: safety and 2-year experience. Am J Neuroradiol 2002;23:1284-90.
91. Badjatia N, Topcuoglu MA, Pryor JC, et al. Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. Am J Neuroradiol 2004;25:819-26.
92. Biondi A, Ricciardi GK, Puybasset L, et al. Intra-arterial nimodipine for the treatment of symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage: preliminary results. Am J Neuroradiol 2004;25:1067-76.
93. Haley EC Jr, Kassell NF, Alves WM, et al. Phase II trial of tirilazad in aneurysmal subarachnoid hemorrhage: a report of the cooperative aneurysm study. J Neurosurg 1995;82:786-90.
94. Dorsch NW, Kassell NF, Sinkula MS. Metaanalysis of trials of tirilazad mesylate in aneurysmal SAH. Acta Neurochir Suppl 2001;77:233-5.
95. Haley EC Jr, Kassell NF, Apperson-Hansen C, et al. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. J Neurosurg 1997;86:467-74.
96. Kassell NF, Haley EC Jr, Apperson-Hansen C, et al. Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand. J Neurosurg 1996;84:221-8.
97. Lanzino G, Kassell NF. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. II. A cooperative study in North America. J Neurosurg 1999;90:1018-24.
98. Lanzino G, Kassell NF, Dorsch NW, et al. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. 1. A cooperative study in Europe, Australia, New Zealand, and South Africa. J Neurosurg 1999;90:1011-17.
99. Grasso G, Buemi M, Alafaci C, et al. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci USA 2002;99:5627-31.
100. Manno EM, Gress DR, Ogilvy CS, et al. The safety and efficacy of cyclosporine A in the prevention of vasospasm in patients with Fisher grade 3 subarachnoid hemorrhages: a pilot study. Neurosurgery 1997;40:289-93.
101. Egemen N, Turker RK, Sanlidilek U, et al. The effect of intrathecal sodium nitroprusside on severe chronic vasospasm. Neurol Res 1993;15:310-15.
102. Thomas JE, McGinnis G. Safety of intraventricular sodium nitroprusside and thiosulfate for the treatment of cerebral vasospasm in the intensive care unit setting. Stroke 2002;33:486-92.
103. Pathak A, Mathuriya SN, Khandelwal N, et al. Intermittent low dose intrathecal sodium nitroprusside therapy for treatment of symptomatic aneurysmal SAH-induced vasospasm. Br J Neurosurg 2003;17:306-10.
104. Ludbrook GL, James MF, Upton RN. The effect of magnesium sulfate on cerebral blood flow velocity, cardiovascular variables, and arterial carbon dioxide tension in awake sheep. J Neurosurg Anesthesiol 1999;11:96-101.
105. Macdonald RL, Curry DJ, Aihara Y, et al. Magnesium and experimental vasospasm. J Neurosurg 2004;100:106-10.
106. Pyne GJ, Cadoux-Hudson TA, Clark JF. Magnesium protection against in vitro cerebral vasospasm after subarachnoid haemorrhage. Br J Neurosurg 2001;15:409-15.
107. Boet R, Mee E. Magnesium sulfate in the management of patients with Fisher grade 3 subarachnoid hemorrhage: a pilot study. Neurosurgery 2000;47:602-7.
108. Brewer RP, Parra A, Lynch J, et al. Cerebral blood flow velocity response to magnesium sulfate in patients after subarachnoid hemorrhage. J Neurosurg Anesthesiol 2001;13:202-6.
109. Chia RY, Hughes RS, Morgan MK. Magnesium: a useful adjunct in the prevention of cerebral vasospasm following aneurysmal subarachnoid haemorrhage. J Clin Neurosci 2002;9:279-81.
110. Veyna RS, Seyfried D, Burke DG, et al. Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage. J Neurosurg 2002;96:510-14.
111. Barile M, van De Wyngaert F, Mbia JJ, et al. Intravenous magnesium sulfate administration in a patient with refractory vasospasm following subarachnoid hemorrhage. Intensive Care Med 2003;29:1182-5.
112. Crago E, Kerr M, Levy E, et al. Effect of continuous magnesium infusion on cerebral vasospasm and 3 month outcomes following subarachnoid hemorrhage [abstr]. Crit Care Med 2005;32:A19.
113. Nagao S, Irie K, Kawai N, et al. Protective effect of mild hypothermia on symptomatic vasospasm: a preliminary report. Acta Neurochir Suppl 2000;76:547-50.
114. Yasui N, Kawamura S, Suzuki A, et al. Role of hypothermia in the management of severe cases of subarachnoid hemorrhage. Acta Neurochir Suppl 2002;82:93-8.
115. Apostolides PJ, Greene KA, Zabramski JM, et al. Intra-aortic balloon pump counterpulsation in the management of concomitant cerebral vasospasm and cardiac failure after subarachnoid hemorrhage: technical case report. Neurosurgery 1996;38:1056-60.
116. Rosen CL, Sekhar LN, Duong DH. Use of intra-aortic balloon pump counterpulsation for refractory symptomatic vasospasm. Acta Neurochir (Wien) 2000;142:25-32.